Cancer and neoplasms
SOR-007 by DFB Soria for Skin Cancer: Likelihood of Approval
Nov
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SOR-007 overview
Paclitaxel is under development for the treatment of pancreatic cyst (mucinous cystic pancreatic neoplasms), pancreatic adenocarcinoma, cutaneous metastasis and actinic keratosis, non-small cell lung cancer and breast cancer. It is a sterile nanoparticulate paclitaxel and administered through intraperitoneal, topical, intracystic, inhalational and intratumoral routes. It was under development for cervical intraepithelial neoplasia, epithelial ovarian cancer and plaque psoriasis. It is developed based on supercritical precipitation (SCP) technology.
It was under development for the treatment of prostate cancer.
For a complete picture of SOR-007’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
